[影响阿比拉治疗转移性割抵抗性前列腺癌患者的并发病:元分析]
Barna Budai1, Bertalan Fekete2, Krisztina Biró3
1Molekuláris Genetikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. budai.barna@oncol.hu.
Magyar onkologia
|March 12, 2026
概括
疼痛和代谢综合征等并发症会影响转移性割抵抗性前列腺癌 (mCRPC) 与阿比拉酸 (AA) 治疗. 需要进一步的研究来通过了解这些预测因素来个性化mCRPC治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 流行病学 流行病学
背景情况:
- 优化转移性前列腺癌的治疗对于降低死亡率至关重要.
- 在转移性割抵抗性前列腺癌 (mCRPC) 中确定阿比拉酸 (AA) 的预测标记是必不可少的.
研究的目的:
- 为了澄清mCRPC患者AA治疗的预测因素.
- 专门研究并发症和共用药物的预测作用.
主要方法:
- 多变量分析的元分析来自120个出版物的结果.
- 包括对至少100个病例的研究.
主要成果:
- 阿片类药物的使用,疼痛,脑血管疾病,脂质失调,他类药物治疗,双酸盐/抗吸收治疗和代谢综合征显著影响病情的进展和生存.
- 这些因素,以及明显的预测因素,影响了接受AA治疗的mCRPC患者的结果.
结论:
- 对并发症的分析是基于有限的观察,需要进一步的研究.
- 澄清并发症和共用药物的预测影响对于个性化mCRPC治疗策略至关重要.
相关概念视频
Treatment Resistent Cancers
1.5K
1.5K
Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K


